Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management

Immune checkpoint inhibitors are a new class of oncologic drugs that act via the inhibition of checkpoints, thereby unlocking the immune system to attack cancer cells. Their emergence has radically changed the concept of therapy in oncologic patients. However, despite their overall favorable profile...

Descripción completa

Detalles Bibliográficos
Autores principales: Apalla, Zoe, Rapoport, Bernardo, Sibaud, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721136/
https://www.ncbi.nlm.nih.gov/pubmed/35005180
http://dx.doi.org/10.1016/j.ijwd.2021.10.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721136/
https://www.ncbi.nlm.nih.gov/pubmed/35005180
http://dx.doi.org/10.1016/j.ijwd.2021.10.005

Ejemplares similares